The combination of recipient HLA-C and donor KIR genotypes can significantly affect OS following HLA-identical sibling HSCT for myeloid disease. Kaplan-Meier plot of overall survival following HLA-identical sibling HSCT for myeloid disease. (i) Recipient C1 negative/donor KIR2DS2 negative (n = 12); (ii) recipient C1 negative/donor KIR2DS2 positive (n = 10); (iii) recipient C1 positive/donor KIR2DS2 negative (n = 43); and (iv) recipient C1 positive/donor KIR2DS2 positive (n = 47).